Targeting LIF/LIFR signaling in cancer

Leukemia inhibitory factor (LIF), and its receptor (LIFR), are commonly over-expressed in many solid cancers and recent studies have implicated LIF/LIFR axis as a promising clinical target for cancer therapy. LIF/LIFR activate oncogenic signaling pathways including JAK/STAT3 as immediate effectors a...

Descripción completa

Detalles Bibliográficos
Autores principales: Viswanadhapalli, Suryavathi, Dileep, Kalarickal V., Zhang, Kam Y.J., Nair, Hareesh B., Vadlamudi, Ratna K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170604/
https://www.ncbi.nlm.nih.gov/pubmed/35685476
http://dx.doi.org/10.1016/j.gendis.2021.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170604/
https://www.ncbi.nlm.nih.gov/pubmed/35685476
http://dx.doi.org/10.1016/j.gendis.2021.04.003

Ejemplares similares